Estrogen and Progesterone Receptor Status as Prognostic Indicators in Patients with Optimally Cytoreduced Stage IIIc Serous Cystadenocarcinoma of the Ovary

By Geisler J.P.   Wiemann M.C.   Miller G.A.   Geisler H.E.  

Gynecologic Oncology, Vol. 60, Iss. 3, 1996-03 ,pp. : 424-427

Academic Press

Access to resources Recommend Favorite

Primary Peritoneal Serous Papillary Carcinoma: A Study of 25 Cases and Comparison with Stage III-IV Ovarian Papillary Serous Carcinoma

By Ben-Baruch G.   Sivan E.   Moran O.   Rizel S.   Menczer J.   Seidman D.S.  

Gynecologic Oncology, Vol. 60, Iss. 3, 1996-03 ,pp. : 393-396

Academic Press

Access to resources Recommend Favorite

Combined Ovarian Serous Papillary and Hepatoid Carcinoma

By Scurry J.P.   Brown R.W.   Jobling T.  

Gynecologic Oncology, Vol. 63, Iss. 1, 1996-10 ,pp. : 138-142

Academic Press

Access to resources Recommend Favorite

Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer

By    

Oncology Reports, Vol. 34, Iss. 5, 2015-01 ,pp. : 2683-2691

Spandidos Publications

Access to resources Recommend Favorite

Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast-Ovarian Cancer Syndrome?

By Goshen R.   Chu W.   Elit L.   Pal T.   Hakimi J.   Ackerman I.   Fyles A.   Mitchell M.   Narod S.A.  

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 477-481

Elsevier

Access to resources Recommend Favorite